Ukuhlola iAvastin kunye neMiphumo Yayo emibi
I-Avastin (bevacizumab) yichiza ejolise kuhlobo lweprotheni (i-VEGF) ekhoyo kwiimvumi ezininzi ze- colon . Ngokwenza njalo, kunceda ukuthintela izicubu ekusasazeni kwezinye iindawo emzimbeni (i- metastasizing ).
Olunye uphando lubonise ukuba ukongeza i-Avastin kwi-regimen ye-chemotherapy kunokunceda abantu abanomdlavuza ogqithiseleyo baphila ixesha elide. Nangona kunjalo, umenzi we-Avastin uye wakhupha izilumkiso malunga neengozi ezithile ezichaphazelekayo kunye neziyobisi, kwaye uphando olupapashwe kwi- Annals ye-Pharmacotherapy luchaze esinye isiphumo esisemgangathweni - ukungaphumeleli kwezintso.
Iinkcukacha zoFundo
Kubalulekile ukuba uqaphele ukuba uphando lwalo luhlobo lwengxelo, oko kuthetha ukuba uthetha ngamava omntu omnye. Ngokukodwa, indoda eneminyaka engama-26 ubudala ene- leiomyosarcoma (uhlobo oluqhelekileyo lomdlavuza ogqithisileyo) lwaphuhliswa kwezintso xa iphathwa ngeAvastin kunye nabaphandi banquma ukuba i-Avastin ibangele.
Iziphumo zengxelo yecala ayibonakali ukuba abantu bathatha iAvastin kufuneka bakhathazeke ngokuphuhliswa kwezintso. Ndiyadlulisa le ngcaciso kunye nje xa umntu ethatha iAvastin zibonakalisa iimpawu zesaphulelo sezintso, ngoko banokuzihlanganisa ngokukhawuleza amabini amabini. Iimpawu zingabandakanya ukugcinwa kwamanzi, ukunyamezela kwegazi, ukunyaniseka kwentliziyo, ukungabikho kwemisipha kunye nokuthinjelwa.
Uphando olunxulumene nazo
- I-Avastin Inokunyuka Ukunyuka kweCaron Cancer
- I-FOLFOX4 I-Avastin: Ngaba kufuneka uzame?
- Ngaba iFOLFOX4 kuwe?
- I-FOLFOX4 I-Drug Combo ebonakaliswe ngempumelelo
Ezinye iiNyango zeCrorectrect Cancer
Ukongeza kwi-Avastin, isiza esichaza ngokukodwa umdlavuza okhohlakeleyo, kukho ezinye iindlela zokwelapha ezikhoyo kwesi sifo.
Ingqalelo, unyango oluthile lwe-colorectal inxalenye enkulu luxhomekeke kubukhulu okanye kwisigaba sesi sifo.
Nazi ezinye iindlela apho i-colorectal iphathwa ngayo:
- ukususwa kokutyunjwa (ukutyunjwa) kwe-tumor, inxalenye echaphazelekayo yesilonda, ukucoca i-lymph nodes kunye neenxalenye zamalungu aqhotyoshelweyo;
- unyango lwe-systemic okanye i-chemotherapy, kuquka iziyobisi ezinjenge-5-FU, capecitabine, kunye neucovorin;
- i-radiotherapy kubantu abanomdlavuza wesibeletho;
- rhoqo emva kokuhlinzwa, i-chemotherapy, kunye nezinye iindlela zokungenelela ukuqinisekisa ukuba umhlaza awuyi kubuya.
Ngethamsanqa, kwiminyaka engama-30 edluleyo, ukuqonda kwethu umhlaza ogqithisiweyo uye waphucula. Ngoku sisazi ngakumbi malunga nale pathogenesis yomhlaza, izizathu zayo, kunye nezinto ezinobungozi. Ukongezelela, ngoku siqonda kakuhle indlela yokusikhusela esi sifo nokukhusela ukugula okukhulu. Ngaphezu koko, iqela leziyobisi lisepayini ukuphatha izigaba zangaphambili zesi sifo, kunye neendlela ezahlukeneyo ziqhubeka nokunyangwa kwesi sifo. Ukujonge phambili, iingcali zithemba ukuba unyango lwesi sifo esibulalayo luya kuphucula kuphela. Nangona kunjalo, indlela engcono kakhulu yokujongana nomhlaza ogqithiseleyo kukubamba ngokukhawuleza ukusebenzisa iindlela zokuhlola njenge-colonoscopy.
Umthombo: Barakat, R. kunye no-Singh, uN. "I-Nephritis Secondary Secondary to Bevacizumab Ukwelashwa kwi-Metastatic Leiomyosarcoma." I-Annals ye-Pharmacotherapy 41.4 (2007): 707-710. Kufumaneka ngomhla we-21 kuMatshi 2007.